Sarepta Therapeutics, Inc. (SRPT)
| Market Cap | 2.20B +24.8% |
| Revenue (ttm) | 1.97B -20.4% |
| Net Income | -136.73M |
| EPS | -1.32 |
| Shares Out | 105.63M |
| PE Ratio | n/a |
| Forward PE | 37.68 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,612,129 |
| Open | 21.49 |
| Previous Close | 21.59 |
| Day's Range | 20.83 - 22.58 |
| 52-Week Range | 14.68 - 25.32 |
| Beta | 0.20 |
| Analysts | Hold |
| Price Target | 22.09 (+5.9%) |
| Earnings Date | Aug 5, 2026 |
About SRPT
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 24 analysts, the average rating for SRPT stock is "Hold." The 12-month stock price target is $22.09, which is an increase of 5.90% from the latest price.
News
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has comm...
Sarepta price target lowered to $35 from $37 at Oppenheimer
Oppenheimer lowered the firm’s price target on Sarepta (SRPT) to $35 from $37 and keeps an Outperform rating on the shares. The firm views the commercial update as balanced. Positively,…
Sarepta reports Q2 adjusted EPS 64c, consensus 49c
Reports Q2 revenue $401.3M, consensus $364.9M. “As I begin my tenure as CEO, I am excited by the strength of Sarepta’s (SRPT) foundation, the impact our therapies are having for…
Sarepta Therapeutics Earnings Call Transcript: Q2 2026
Q2 2026 saw operating profitability, strong cash growth, and stable Duchenne therapy demand. Revenue guidance was narrowed, with second-half sales expected to dip before a rebound in 2027 as commercial initiatives gain traction. Multiple regulatory and clinical milestones are upcoming.
Sarepta Therapeutics Quarterly report: Q2 2026
Sarepta Therapeutics has published its Q2 2026 quarterly earnings report on August 5, 2026.
Sarepta Therapeutics Earnings release: Q2 2026
Sarepta Therapeutics released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Sarepta Therapeutics Slides: Q2 2026
Sarepta Therapeutics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter of 2026...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on July 28, 2026, that were previously ap...
Morgan Stanley says Sarepta’s CEO transition brings clarity ahead of catalysts
Morgan Stanley notes that Sarepta (SRPT) announced the appointment of Michael Severino as CEO succeeding Doug Ingram, who will remain in an advisory role through year-end 2026. The CEO transition…
Sarepta names former Abbvie president as CEO as Ingram retires
Sarepta Therapeutics said on Monday it appointed former Tessera Therapeutics CEO Michael Severino its chief executive, effective July 28. The longtime AbbVie executive, will succeed Doug Ingram.
Sarepta appoints Severino as Chief Executive Officer
Sarepta (SRPT) Therapeutics announced the appointment of Michael Severino, M.D., as chief executive officer, effective July 28, 2026. Severino, who was previously CEO of Tessera Therapeutics, will als...
Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as c...
Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2026 financial results after the Nas...
Citi sees intensifying competition for Sarepta from Dyne Therapeutics
Citi sees increased competition for Sarepta (SRPT) after the FDA accepted Dyne Therapeutics’ (DYN) application for z-rostudirsen in Duchenne muscular dystrophy. Citi sees z-rostudirsen differentiating...
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Sarepta Therapeutics, Inc. (SRPT)
SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) against ce...
Sarepta price target lowered to $20 from $23 at Piper Sandler
Piper Sandler lowered the firm’s price target on Sarepta (SRPT) to $20 from $23 and keeps a Neutral rating on the shares. The firm lowers its Q2 Elevidys U.S. revenue…
Sarepta upgraded to Outperform from Peer Perform at Wolfe Research
Wolfe Research upgraded Sarepta (SRPT) to Outperform from Peer Perform with a $27 price target Share gains for Sarepta have been “transient” but the firm believes that this will shift…
H.C. Wainwright says Sarepta news does not signal full approvals
H.C. Wainwright analyst Mitchell Kapoor reiterates a Sell rating on Sarepta (SRPT) with a $5 price target after the FDA accepted the supplemental new drug applications for Amondys 45 and…
Sarepta announces FDA acceptance of sNDAs for AMONDYS 45, VYONDYS 53
Sarepta (SRPT) Therapeutics announced that the U.S. Food and Drug Administration has accepted for filing the supplemental New Drug Applications for AMONDYS 45 and VYONDYS 53 for the treatment of…
Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA...
Sarepta Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Leadership transition is underway with a focus on strategic priorities for 2026, including ELEVIDYS stabilization, pipeline advancement, and financial strength. Strong financials, robust pipeline progress, and positive regulatory outlook support growth, with pivotal siRNA trials planned for next year.
Sarepta Therapeutics Transcript: AGM 2026
The meeting approved all five proposals, including director elections, executive compensation, and new equity plans. Shareholders raised questions about board composition, CEO succession, and compensation, with the board emphasizing stability and ongoing performance improvements.
Sarepta Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the ...
Sarepta price target lowered to $19 from $20 at Evercore ISI
Evercore ISI lowered the firm’s price target on Sarepta (SRPT) to $19 from $20 and keeps an In Line rating on the shares.